Paul Stoffels, J&J CSO (Andrew Harnik/AP Images)
October 12, 2021 07:41 AM EDTUpdated 04:55 PM
People

J&J sci­ence lead Paul Stof­fels set to re­tire amid brain trust shake­up at world's largest drug­mak­er

Kyle Blankenship

Paul Stof­fels, the sci­en­tif­ic lead be­hind J&J’s re­fresh of its hal­lowed Janssen unit and the cre­ation of the com­pa­ny’s sin­gle-shot Covid-19 vac­cine, will re­tire at …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

2024's bio­phar­ma win­ners and losers; Ca­griSe­ma falls short; Mer­ck swings Chi­na GLP-1 deal; and more

A service from the Financial Times